TY - JOUR
T1 - Cord blood transplantation in patients with hemoglobinopathies
AU - Boncimino, Agata
AU - Bertaina, Alice
AU - Locatelli, Franco
PY - 2010
Y1 - 2010
N2 - Despite the optimization of conventional treatment, both thalassemia and sickle cell disease are still associated with significant morbidity and mortality, especially in developing countries. Allogeneic transplantation of hematopoietic progenitors is the only curative treatment and represents an attractive option for these patients. In view of the low incidence of graft-versus-host disease associated with the procedure, allogeneic cord blood transplantation (CBT) is particularly appealing for patients with non-malignant disorders. Available evidence indicates that related donor CBT is a safe and effective option for patients with hemoglobinopathies, able to offer results at least as good as those reported using bone marrow cells. (C) 2010 Elsevier Ltd. All rights reserved.
AB - Despite the optimization of conventional treatment, both thalassemia and sickle cell disease are still associated with significant morbidity and mortality, especially in developing countries. Allogeneic transplantation of hematopoietic progenitors is the only curative treatment and represents an attractive option for these patients. In view of the low incidence of graft-versus-host disease associated with the procedure, allogeneic cord blood transplantation (CBT) is particularly appealing for patients with non-malignant disorders. Available evidence indicates that related donor CBT is a safe and effective option for patients with hemoglobinopathies, able to offer results at least as good as those reported using bone marrow cells. (C) 2010 Elsevier Ltd. All rights reserved.
KW - N/A
KW - N/A
UR - http://hdl.handle.net/10807/251674
U2 - 10.1016/j.transci.2010.03.006
DO - 10.1016/j.transci.2010.03.006
M3 - Article
SN - 1473-0502
VL - 42
SP - 277
EP - 281
JO - Transfusion and Apheresis Science
JF - Transfusion and Apheresis Science
ER -